We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
US drug major Merck & Co. has announced that its Canadian
unit, Merck Frosst, will no longer supply local pharmacies it believes to be
engaged in the country's lucrative export trade with the US.
UK- and Sweden-based drug producer AstraZeneca has suffered a further setback
on its Exanta (ximelagatran) treatment, indicated for stroke and thromboembolic
complications associated with atrial fibrillation.
European Union (EU) judicial authorities have issued a decision allowing generic
drugmakers to market cheap versions of UK drug major GlaxoSmithKline (GSK)'s
Paxil depression therapy.
According to reports in the UK press, the generics unit of Swiss drug major
Novartis is currently under investigation by both anti-fraud agency SFO and
healthcare provider the National Health Service (NHS) on alleged price-fixing
charges.
Indian antibiotics producer Orchid Chemicals has claimed that it will increase
its stake in US drug discovery joint venture Bexel Pharmaceuticals to 75%.
US pharmaceuticals products distributor Cardinal
Health and Japanese drugmaker Eisai have announced a new multi-year agreement,
reversing Eisai's decision last week to cancel the two companies' existing arrangements.